AR093225A1 - Proteinas protozoarias variables de superficie (vsp, por su sigla en ingles) como vehiculos para la administracion de farmacos - Google Patents

Proteinas protozoarias variables de superficie (vsp, por su sigla en ingles) como vehiculos para la administracion de farmacos

Info

Publication number
AR093225A1
AR093225A1 ARP130102433A ARP130102433A AR093225A1 AR 093225 A1 AR093225 A1 AR 093225A1 AR P130102433 A ARP130102433 A AR P130102433A AR P130102433 A ARP130102433 A AR P130102433A AR 093225 A1 AR093225 A1 AR 093225A1
Authority
AR
Argentina
Prior art keywords
vsp
therapeutic agent
vehicle
composition
vehicles
Prior art date
Application number
ARP130102433A
Other languages
English (en)
Inventor
Lujan Hugo
Piaggio Eliane
Klatzmann David
Original Assignee
Consejo Nac De Investig Cientificas Y Tecn (Conicet)
Univ Catolica De Cordoba
Inserm (Institut Nat De La Sante Et De La Rech Medicale)
Centre Nat De La Rech Scient - Cnrs
Hopitaux Paris Assist Publique
Univ Pierre Et Marie Curie (Paris Vi)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac De Investig Cientificas Y Tecn (Conicet), Univ Catolica De Cordoba, Inserm (Institut Nat De La Sante Et De La Rech Medicale), Centre Nat De La Rech Scient - Cnrs, Hopitaux Paris Assist Publique, Univ Pierre Et Marie Curie (Paris Vi) filed Critical Consejo Nac De Investig Cientificas Y Tecn (Conicet)
Publication of AR093225A1 publication Critical patent/AR093225A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Reivindicación 1: Una composición terapéutica que comprende un vehículo VSP y un agente terapéutico. Reivindicación 4: La composición de cualquiera de las reivindicaciones 1 a 3, donde el vehículo VSP se selecciona del grupo consistente en una VSP, una proteína similar a VSP, un fragmento de proteína VSP o similar a VSP, un derivado de proteína VSP o similar a VSP y una combinación de dos o más de dichos vehículos VSP. Reivindicación 13: La composición de cualquiera de las reivindicaciones de 1 a 12, donde el agente terapéutico es un agente biológico. Reivindicación 18: La composición de la reivindicación 15, donde el péptido bioactivo es un análogo de la insulina. Reivindicación 34: Un método para aumentar la resistencia de un agente terapéutico a la degradación enzimática, el cual comprende combinar un vehículo VSP y un agente terapéutico, donde el vehículo VSP se puede enlazar al agente terapéutico, y donde la combinación del vehículo VSP y el agente terapéutico resulta en un aumento en la resistencia del agente terapéutico a la degradación enzimática. Reivindicación 36: Un método para aumentar la capacidad de adherencia de un agente terapéutico a las células epiteliales de las mucosas, el cual comprende combinar un vehículo VSP y un agente terapéutico, donde el vehículo VSP se puede enlazar al agente terapéutico, y donde la combinación del vehículo VSP y el agente terapéutico resulta en un aumento en la capacidad de adherencia del [agente] terapéutico a las células epiteliales de las mucosas. Reivindicación 61: Un complejo para la administración de fármacos caracterizado porque comprende un vehículo VSP y al menos un agente terapéutico.
ARP130102433A 2012-07-06 2013-07-08 Proteinas protozoarias variables de superficie (vsp, por su sigla en ingles) como vehiculos para la administracion de farmacos AR093225A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668865P 2012-07-06 2012-07-06
US13/843,766 US9457096B2 (en) 2012-07-06 2013-03-15 Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery

Publications (1)

Publication Number Publication Date
AR093225A1 true AR093225A1 (es) 2015-05-27

Family

ID=49878968

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102433A AR093225A1 (es) 2012-07-06 2013-07-08 Proteinas protozoarias variables de superficie (vsp, por su sigla en ingles) como vehiculos para la administracion de farmacos

Country Status (10)

Country Link
US (3) US9457096B2 (es)
EP (2) EP2869829B1 (es)
CN (1) CN104994867A (es)
AR (1) AR093225A1 (es)
AU (2) AU2013285099A1 (es)
BR (1) BR112015000183B1 (es)
CA (1) CA2878322C (es)
MX (1) MX353649B (es)
NZ (1) NZ704285A (es)
WO (1) WO2014006502A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200276276A1 (en) 2016-03-01 2020-09-03 Ascendis Pharma Bone Diseases A/S PTH Prodrugs
FI3518960T3 (fi) * 2016-09-29 2023-10-04 Ascendis Pharma Bone Diseases As Annostusohjelma kontrolloidusti vapautuvalle PTH-yhdisteelle
MX2019003182A (es) 2016-09-29 2019-08-05 Ascendis Pharma Bone Diseases As Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
CN107083961B (zh) * 2017-05-10 2019-04-26 中国矿业大学 基于压裂圈的强地压巷道应力转移方法
EP3466963A1 (en) * 2017-10-05 2019-04-10 Suigeneris Farmacosmetics, S.L. Anticancer peptides and uses thereof
AU2020334967A1 (en) * 2019-08-16 2022-04-07 Applied Molecular Transport Inc. Compositions and particles for payload delivery
EP4144752A1 (en) * 2021-09-02 2023-03-08 Sorbonne Universite Viral-like particles for the treatment or prevention of an infection by a coronaviridae virus
KR20230083100A (ko) * 2021-12-02 2023-06-09 삼성전자주식회사 폴리펩티드, 이를 포함하는 포토레지스트 조성물 및 이를 이용한 패턴 형성 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
TR200400295T2 (tr) 2001-05-21 2005-04-21 Nektar Therapeutics Kimyasal olarak modifiye edilmiş ensülin'in akçiğer yoluyla verilmesi
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7049286B2 (en) 2001-08-30 2006-05-23 Diatos, S.A. Insulin conjugates and methods of use thereof
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
EP1843790A2 (en) 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
AU2006257792A1 (en) 2005-06-13 2006-12-21 Mdrna, Inc. Transmucosal delivery of peptide derivatives
BRPI0520362B1 (pt) 2005-07-08 2017-10-17 Biocon Limited Preparation of insulin conjugates
DK1934252T3 (en) 2005-10-13 2015-08-31 Biocon Ltd METHOD FOR PRODUCING insulin conjugates
CA2649235A1 (en) 2006-05-09 2007-11-15 Frantisek Hubalek Insulin derivative
MX2011005815A (es) 2008-12-02 2011-09-30 Consejo Nac Invest Cient Tec Protozoo modificado que expresa al menos dos proteinas variables de superficie (vsp), vacuna que lo comprende, procedimientos, usos y metodos.
BRPI1007466A2 (pt) 2009-01-28 2018-06-12 Smartcells Inc conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
UY33297A (es) 2010-03-29 2011-09-30 Inst Nat Sante Rech Med Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas

Also Published As

Publication number Publication date
BR112015000183B1 (pt) 2022-12-13
US9757471B2 (en) 2017-09-12
US20140011739A1 (en) 2014-01-09
US20150157735A1 (en) 2015-06-11
AU2017265167B2 (en) 2019-10-31
CA2878322C (en) 2021-11-16
EP3398610B1 (en) 2020-09-09
EP3398610A1 (en) 2018-11-07
CN104994867A (zh) 2015-10-21
AU2013285099A1 (en) 2015-02-19
MX2015000016A (es) 2015-10-29
CA2878322A1 (en) 2014-01-09
AU2017265167A1 (en) 2017-12-14
EP2869829A1 (en) 2015-05-13
EP2869829B1 (en) 2018-09-12
US20180228913A1 (en) 2018-08-16
WO2014006502A8 (en) 2014-12-11
BR112015000183A2 (pt) 2018-03-20
NZ704285A (en) 2018-04-27
MX353649B (es) 2018-01-22
US9457096B2 (en) 2016-10-04
WO2014006502A1 (en) 2014-01-09

Similar Documents

Publication Publication Date Title
AR093225A1 (es) Proteinas protozoarias variables de superficie (vsp, por su sigla en ingles) como vehiculos para la administracion de farmacos
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
PE20142168A1 (es) Composicion y metodo para el diagnostico y el tratamiento de las enfermedades asociadas a la degeneracion de las neuritas
ECSP099332A (es) Moléculas de enlace de lingo y uso farmacéutico de las mismas
PE20140797A1 (es) COMPOSICIONES Y METODOS PARA ADMINISTRACION DE ARNm
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
CL2016001405A1 (es) A peptide mixture
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
AR088513A1 (es) Inmunoenlazantes dirigidos contra esclerostina
WO2014062697A3 (en) Drug delivery conjugates containing unnatural amino acids and methods for using
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
BR112015021709A2 (pt) poli(beta-amino éster)es modificados para administração de fármacos
BR112015011244A2 (pt) Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
PE20131065A1 (es) Composiciones farmaceuticas combinadas y metodo de tratamiento del vertigo, la cinetosis y la distonia vegetativa-vascular
CL2009001077A1 (es) Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
BR112015015864A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112013000842A2 (pt) composições farmacêuticas, método de tratamento de condição de etiologia funcional do trato gastrointestinal e uso de forma potenciada ativada de anticorpo para a proteína s-100, de forma potenciada ativada de anticorpo para histamina e de forma potenciada ativada de anticorpo para a tnf-alfa.
BR112014024358A2 (pt) uso de iduronate-2-sulfatase por via subcutânea e kit
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada

Legal Events

Date Code Title Description
FC Refusal